Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TuHURA Biosciences, Inc./NVDMPI · Entity 6601 | Director | June 26, 2020 | June 30, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TuHURA Biosciences, Inc./NV
Report date June 26, 2020 · Filed June 30, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectHeld by J.G. Cranston & Associates, Inc. | 332 |
Reported balance
After 2020-06-30 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-06-30 · Other · Disposed 8 · Balance 332 F1: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.61 · Expires 2029-09-05 | Direct | 75,000 |
Reported balance
After 2020-06-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-06-26 · Grant · Acquired 39,567 · Balance 75,000 F2: On September 5, 2019, the reporting person received options to purchase 39,567 shares which were subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the 2020 Annual Meeting of Stockholders. Stockholder approval of the increase was obtained on June 26, 2020. F3: The shares subject to the option vest in twelve (12) equal monthly installments beginning on October 5, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock.
F2: On September 5, 2019, the reporting person received options to purchase 39,567 shares which were subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the 2020 Annual Meeting of Stockholders. Stockholder approval of the increase was obtained on June 26, 2020.
F3: The shares subject to the option vest in twelve (12) equal monthly installments beginning on October 5, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2020 Filed Jun 30, 2020 16:16 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 8 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-20-016317 · ownership.xml · nonDerivative · entry 1 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by J.G. Cranston & Associates, Inc. Disclosed balance after: 332 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 16:16 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOption (Right to Buy) · Derivative | 39,567 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001213900-20-016317 · ownership.xml · derivative · entry 2 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 39,567 shares Expires 2029-09-05 F2 · kind: On September 5, 2019, the reporting person received options to purchase 39,567 shares which were subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the 2020 Annual Meeting of Stockholders. Stockholder approval of the increase was obtained on June 26, 2020. F3 · derivative.exercise_date: The shares subject to the option vest in twelve (12) equal monthly installments beginning on October 5, 2019. Read SEC document |
| March 31, 2020 Filed Mar 31, 2020 16:16 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 8 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-20-008217 · ownership.xml · nonDerivative · entry 1 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by J.G. Cranston & Associates, Inc. Disclosed balance after: 324 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 16:15 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 8 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-20-000016 · delmarph_fm4dec312019.xml · nonDerivative · entry 1 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by J.G. Cranston & Associates, Inc. Disclosed balance after: 316 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 16:22 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 8 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-19-000815 · delmarph_fm4sept302019.xml · nonDerivative · entry 1 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by J.G. Cranston & Associates, Inc. Disclosed balance after: 308 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| September 05, 2019 Filed Sep 9, 2019 16:36 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 35,433 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0000905718-19-000761 · delmarph_fm4sept52019.xml · derivative · entry 2 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,433 Underlying: Common Stock · 35,433 shares Expires 2029-09-05 F2 · derivative.exercise_date: The shares subject to the option vest in twelve (12) equal monthly installments beginning on October 5, 2019. Read SEC document |
| September 05, 2019 Filed Sep 9, 2019 16:36 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 39,567 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0000905718-19-000761 · delmarph_fm4sept52019.xml · derivative · entry 1 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,567 Underlying: Common Stock · 39,567 shares Expires 2029-09-05 F1 · derivative.exercise_date: Subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the next annual meeting, the shares subject to the option vest in twelve (12) equal monthly installments beginning on October 5, 2019. Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 16:20 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 8 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-011880 · ownership.xml · nonDerivative · entry 1 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by J.G. Cranston & Associates, Inc. Disclosed balance after: 300 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F2 · balance_after: On May 8, 2019, the issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| April 30, 2019 Filed May 1, 2019 18:29 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | Disposition to issuerPerformance Stock Units · Derivative | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-007624 · ownership.xml · derivative · entry 1 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2022-07-07 F1 · derivative.exercise_price: Each performance stock unit represents the right to receive one share of common stock, to vest upon achievement of specified targets related to the Company's financial performance. Such performance stock units were unvested. F1 · derivative.exercise_date: Each performance stock unit represents the right to receive one share of common stock, to vest upon achievement of specified targets related to the Company's financial performance. Such performance stock units were unvested. Read SEC document |
| March 29, 2019 Filed Apr 1, 2019 16:37 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 71 | $0.49 | $34.79 |
DisclosureSEC source: 0001213900-19-005503 · ownership.xml · nonDerivative · entry 1 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by J.G. Cranston & Associates, Inc. Disclosed balance after: 2,912 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| December 31, 2018 Filed Jan 2, 2019 18:19 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 71 | $0.34 | $24.27 |
DisclosureSEC source: 0001213900-19-000053 · ownership.xml · nonDerivative · entry 1 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by J.G. Cranston & Associates, Inc. Disclosed balance after: 2,841 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 16:40 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001213900-18-015518 · ownership.xml · derivative · entry 1 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-11-08 F1 · derivative.exercise_date: The shares subject to the option vest in twelve (12) equal monthly installments beginning on December 8, 2018. Read SEC document |
| September 28, 2018 Filed Oct 1, 2018 16:07 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 71 | $3.20 | $227.20 |
DisclosureSEC source: 0001213900-18-013296 · ownership.xml · nonDerivative · entry 1 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by J.G. Cranston & Associates, Inc. Disclosed balance after: 2,770 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 16:40 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 71 | $3.20 | $227.20 |
DisclosureSEC source: 0001213900-18-008712 · ownership.xml · nonDerivative · entry 1 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by J.G. Cranston & Associates, Inc. Disclosed balance after: 2,699 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| March 30, 2018 Filed Apr 3, 2018 16:05 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 71 | $3.20 | $227.20 |
DisclosureSEC source: 0001213900-18-003986 · f4033018cranston_delmar.xml · nonDerivative · entry 1 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by J.G. Cranston & Associates, Inc. Disclosed balance after: 2,628 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 16:57 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 71 | $3.20 | $227.20 |
DisclosureSEC source: 0000905718-18-000013 · cranston_form4dec312017.xml · nonDerivative · entry 1 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by J.G. Cranston & Associates, Inc. Disclosed balance after: 2,557 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 19:52 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 71 | $3.20 | $227.20 |
DisclosureSEC source: 0001213900-17-010210 · f4092917cranston_delmarpharm.xml · nonDerivative · entry 1 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Note Disclosed balance after: 2,486 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F2 · ownership.nature: Shares are held by J.G. Cranston & Associates, Inc. Read SEC document |
| July 07, 2017 Filed Jul 11, 2017 21:34 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantPerformance Stock Units · Derivative | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-17-007476 · f4070717cranston_delmarpharm.xml · derivative · entry 2 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2022-07-07 F2 · derivative.exercise_price: Subject to stockholder approval of the Company's 2017 Omnibus Equity Incentive Plan at the Company's annual meeting, each performance stock unit represents the right to receive one share of common stock upon vesting of the unit based on achievement of specified targets related to the Company's financial performance. F2 · derivative.exercise_date: Subject to stockholder approval of the Company's 2017 Omnibus Equity Incentive Plan at the Company's annual meeting, each performance stock unit represents the right to receive one share of common stock upon vesting of the unit based on achievement of specified targets related to the Company's financial performance. Read SEC document |
| July 07, 2017 Filed Jul 11, 2017 21:34 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001213900-17-007476 · f4070717cranston_delmarpharm.xml · derivative · entry 1 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2027-07-07 F1 · derivative.exercise_date: 12,000 options vest on June 30, 2018, and 3,000 options vest each three months thereafter starting September 30, 2018. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 14:27 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 71 | $3.20 | $227.20 |
DisclosureSEC source: 0001213900-17-007145 · f4063017cranston_delmar.xml · nonDerivative · entry 1 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Note Disclosed balance after: 2,415 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F2 · ownership.nature: Shares are held by J.G. Cranston & Associates, Inc. Read SEC document |
| June 26, 2017 Filed Jun 28, 2017 11:31 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | PurchaseCommon Stock | 2,083 | $3.60 | $7,498.80 |
DisclosureSEC source: 0001213900-17-006882 · f4062617cranston_delmarpha.xml · nonDerivative · entry 1 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Note Disclosed balance after: 2,344 F1 · price: The Reporting Person purchased the shares in a private transaction for an aggregate purchase price of CDN $10,000. Reported price is based on exchange rate of 0.75. F2 · ownership.nature: Shares are held by J.G. Cranston & Associates, Inc. Read SEC document |
| March 31, 2017 Filed Apr 3, 2017 18:14 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 71 | $3.20 | $227.20 |
DisclosureSEC source: 0001213900-17-003268 · f4033117cranston_delmar.xml · nonDerivative · entry 1 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Note Disclosed balance after: 261 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F2 · ownership.nature: Shares are held by J.G. Cranston & Associates, Inc. Read SEC document |
| December 31, 2016 Filed Jan 3, 2017 13:54 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 71 | $3.20 | $227.20 |
DisclosureSEC source: 0001213900-17-000022 · f4123116cranston_delmar.xml · nonDerivative · entry 1 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Note Disclosed balance after: 190 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F2 · ownership.nature: Shares are held by J.G. Cranston & Associates, Inc. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 13:57 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | OtherCommon Stock | 71 | $3.20 | $227.20 |
DisclosureSEC source: 0001213900-16-017304 · f4100316cranston_delmar.xml · nonDerivative · entry 1 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Note Disclosed balance after: 119 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F2 · ownership.nature: Share are held by J.G. Cranston & Associates, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.